(Q42995701)

12 November 2017

title

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia (English)

1 reference

randomized controlled trial

12 November 2017

1 reference

1 reference

1 reference

1 reference

1 reference

M L Shiffman

1

1 reference

12 November 2017

C M Hofmann

2

1 reference

12 November 2017

M J Contos

3

1 reference

12 November 2017

V A Luketic

4

1 reference

12 November 2017

A J Sanyal

5

1 reference

12 November 2017

R K Sterling

6

1 reference

12 November 2017

A Ferreira-Gonzalez

7

1 reference

12 November 2017

A S Mills

8

1 reference

12 November 2017

C Garret

9

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

12 November 2017

1 reference

12 November 2017

volume

117

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

1164-1172

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

The long-term pathological evolution of chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Liver fibrosis and extracellular matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Type IV collagen and laminin-related antigens in human serum in alcoholic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Long-term follow-up of chronic active hepatitis of moderate severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

The prognosis of chronic aggressive hepatitis. A clinical and morphological follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970402-6

10.1016/S0016-5085(99)70402-6

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference